1. Nathan DM, Buse JB, Davidson MB et al. American Diabetes Association; European Association for the Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193–203.
2. Rodbard HW, Jellinger PS, Davidson JA еt al. Statement by an American Association of Clinical Endocrinologists / American College of +Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control. Endocr Pract 2009; 15 (6): 540–59.
3. Консенсус РАЭ. Сахаоный диабет, 2011; 4, в печати.
4. Miller ME, Byington RP, Goff DC Jr et al (Action to Control Cardiovascular Risk in Diabetes Study Group). Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545–59.
5. Duckworth W, Abraira C,Moritz T et al (VADT Investigators). Glucose control and vascular complications in veterans with type 2 diabetes [published correction appears in N Engl J Med 2009; 361: 1024–5, 1028]. N Engl J Med 2009; 360: 129–39.
6. Patel A, MacMahon S, Chalmers J et al (ADVANCE Collaborative Group). Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560–72.
7. Skyler JS, Bergenstal R, Bonow RO. A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE and VA Diabetes Trials. Diabetes Care 2009; 32: 187–92.
8. Center for Drug Evaluation and Research. Guidance for industry diabetes mellitus: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes [Internet] 2008. Available from http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf.
9. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352, 854–65.
10. Wiernsperger NF. Metformin: intrinsic vasculoprotective properties. Diabetes Technol Ther 2000; 2: 259–72.
11. Leverve XM, Guigas B, Detaille D et al. Mitochondrial metabolism and type-2 diabetes: a specific target of metformin. Diabetes Metab 2003; 29: 6S88–6S94.
12. Grant PJ. Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab 2003; 29: 6S44–6S52.
13. Beisswenger P, Ruggiero-Lopez D. Metformin inhibition of glycation processes. Diabetes Metab 2003; 29: 6S95–6S103.
14. Смирнова О.М. Применение метформина в настоящем и будущем. Cons. Med. 2010; 12: 10–7.
15. Oates MS, Snah RR, Idle JR et al. Influence of oxidation polymorphism on phenformin kinetics and dynamics. Clin Pharmacol Ther 1983; 34: 827–34.
16. Rousse R, Travert F, Pasquet B. Metformin Use and Mortality Among Patients With Diabetes and Atherothrombosis. Arch Intern Med 2010; 170 (21): 1892–9.
17. Lipska K, Bailey C, Inzucci S. Use of metformin in the setting of mild-to moderate renal insufficient. Diabetes Care 2011; 34: 1431–7.
18. Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study. Diabet Med 2002; 19: 279–84.
19. Timmins P, Donahue S, Meeker J, Marathe P. Steady-state pharmacokinetics of a novel extended-release Metformin formulation. Clin Pharmacokinet 2005; 44 (7): 721–9.
20. Blonde L, Dailey GE, Jabbour SA et al. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Curr Med Res Opin 2004; 20 (4): 565–72.
21. Donnelly LA, Morris AD, Pearson ER. Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population-based study. Diabetes, Obesity and Metabolism 2009; 11: 338–42.
22. Feher M, Al-Murat M, Brake J et al. Tolerability of prolonged-release metformin (Glucophage® SR) in individuals intolerant to standard metformin – results from four UK centres. Br J Diabetes Vasc Dis 2007; 7: 225–8.
23. Fujioka K, Brazg RL, Raz I et al. Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double-blind, placebo-controlled studies. Diabetes, Obesity and Metabolism 2005; 7: 28–39.

О.Ю.Сухарева, М.В.Шестакова

ФГБУ Эндокринологический научный центр Минздравсоцразвития РФ